Ballicules.com

Terbinafine

LAMISIL

What it isAllylamine inhibiting squalene epoxidase; dermatophyte onychomycosis and tinea.

Why this oneFar higher cure rates in nail infection than topical agents or itraconazole, and it concentrates in keratin.

What limits itHepatotoxicity means baseline liver tests. It is a strong CYP2D6 inhibitor, which matters for metoprolol and tricyclics; taste loss can be permanent.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Fingernail onychomycosisAdults250 mg QD250 mg QD × 6 weeks250 mg QD
Toenail onychomycosisAdults250 mg QD250 mg QD × 12 weeks250 mg QD

Renal Undefined

Hepatic Contraindicated in chronic or active liver disease

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Postmarketing data insufficient; no fetal harm in animal studies

Lactation Present in human milk (oral)

NO BOXED WARNINGS

Principal riskHepatotoxicity; a strong CYP2D6 inhibitor

Cost, est. cash$10–$300/month

Generic entry2007

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger0 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryC

Defining liabilityLocal irritation or hypersensitivity; systemic toxicity is minimal with correct local use.

Mechanism of action: Terbinafine ballicule

Terbinafine ballicule: receptor binding, kinetics and half-life diagram

Open Terbinafine in the interactive console ↗

Memory aids: mascots and interaction avatars

Terbinafine LAMISIL mascot mnemonic cartoon
“Llama’s ill, turban’s fine”
Strong CYP2D6 inHibitor
Terbinafine CYP2D6 inhibitor avatar
CYP2D6 inhibitor (strong)

Open Terbinafine in the interactive console ↗